Haleon PLC Sponsored ADR
HLN Healthcare Drug Manufacturers Specialty & Generic
Haleon PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $14.5 billion, up 1.33% from fiscal 2024.
Follow HLN
Alert me
Haleon PLC Sponsored ADR (HLN) Operating margin
Haleon PLC Sponsored ADR's operating margin over the twelve months to 30 September 2024 was 17.9%. Over the past ten years it has ranged from 16.8% (fiscal 2022) to 40.9% (fiscal 2021); the current reading is higher than 57% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 0.00% and above the Healthcare sector median of 0.00%.
Operating margin, annual
Embed this chart
Annual newest first
| Period | Operating margin | Change (points) |
|---|---|---|
| FY2025 | 21.9% | 2.23 |
| FY2024 | 19.6% | 1.98 |
| FY2023 | 17.7% | 0.85 |
| FY2022 | 16.8% | (24.11) |
| FY2021 | 40.9% | 4.30 |
| FY2020 | 36.6% | (4.21) |
| FY2019 | 40.8% | — |
Quarterly newest first
| Period | Operating margin | Change (points) |
|---|---|---|
| Sep 2024 | 25.4% | 2.92 |
| Mar 2024 | 22.4% | 1.57 |
| Sep 2023 | 20.9% | 20.87 |
| Jun 2023 | 0.00% | (21.00) |
| 1 more quarters | Free account |
Against its own ten years
Operating margin against peers
| Company | Operating margin |
|---|---|
| UTHR United Therapeutics Corporation compare | 41.5% |
| ZTS Zoetis Inc. compare | 37.1% |
| NBIX Neurocrine Biosciences, Inc. compare | 24.0% |
| HLN Haleon PLC Sponsored ADR | 17.9% |
| TAK Takeda Pharmaceutical Co. compare | 11.6% |
| RDY Dr. Reddy's Laboratories Ltd compare | 9.20% |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 7.84% |
| ELAN Elanco Animal Health Incorporated compare | 1.61% |
| VTRS Viatris Inc. compare | −0.03% |
| Drug Manufacturers Specialty & Generic industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Operating margin is
EBIT Margin tells an investor how much operating profit, before interest and taxes, a company keeps from each unit of revenue.
EBIT ÷ Revenue
More on HLN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- Beneish M-score
- The full statement